Tags: prostate | cancer | therapy

New Therapy Targets Hard-to-Treat Prostate Cancer

New Therapy Targets  Hard-to-Treat Prostate Cancer
(Copyright DPC)

Wednesday, 14 February 2018 03:09 PM

The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson's Erleada treatment for use in prostate cancer patients whose cancer has not spread but continues to grow despite hormone therapy.

The drug is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer, the regulator said. 

The approval was based on a trial goal that measured the length of time tumors did not spread to other parts of the body, or death occurred after starting the treatment, the FDA said.

According to the National Cancer Institute, about 161,360 men were diagnosed with prostate cancer in 2017, and 26,730 were expected to die of the disease.

The drug is expected to compete with Pfizer's Xtandi, which has shown impressive trial data in the treatment of prostate cancer.

Earlier this month, data from a study testing Xtandi showed that use of the drug in early stage prostate cancer on top of standard hormone therapy reduced the risk of the disease spreading or death by 71 percent compared with hormone therapy alone.

© 2018 Thomson/Reuters. All rights reserved.

   
1Like our page
2Share
Health-News
The FDA has approved Johnson & Johnson's Erleada treatment for use in prostate cancer patients whose cancer continues to grow despite hormone therapy.
prostate, cancer, therapy
170
2018-09-14
Wednesday, 14 February 2018 03:09 PM
Newsmax Media, Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved